Navigation Links
Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
Date:5/22/2008

BETHESDA, Md., May 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that the company will provide an update on the phase 1 clinical trial underway for its BiTE(R) antibody MT103/MEDI-538 at the 10th International Conference on Malignant Lymphomas, taking place June 4-7 in Lugano, Switzerland.

The presentation, entitled, "Anti-CD19 BiTE Antibody MT103 (MEDI-538) Induces Durable Objective Responses in Patients with Relapsed Non-Hodgkin's Lymphoma (NHL). Update from Ongoing Phase I Study MT103-104" will take place during Poster Session I from 8:00am to 6:00pm on June 5th, 2008 in the Marquee Parco Ciani. Meeting abstracts will first be available during the week of the conference.

The 10th International Conference on Malignant Lymphoma gathers 3,000 leading physicians from all over the world: hematologists, clinical oncologists, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms, including multiple myeloma and CLL.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-destroying, T cells against tumor cells, and represent a new therapeutic approach to cancer therapy. BiTE antibodies have been shown to induce an immunological synapse between a T cell and a tumor cell in the same manner as observed during physiological T cell attacks. These cytolytic synapses enable the delivery of cytotoxic proteins from T cells into tumor cells, ultimately inducing a self-destruction process in the tumor cell referred to as apoptosis, or programmed cell death. In the presence of BiTE antibodies, T cells have been demonstrated to serially eliminate tumor cells, which explains the activity of BiTE antibodies at very low concentrations and at very low ratios of T cells to target cells. Through the process of kill
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
2. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
3. Micromet Presents Safety and Efficacy Data from Primate Studies With Two New BiTE Antibodies Developed for Treatment of Leukaemia and Melanoma
4. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
7. Micromet Announces Changes in Management Team
8. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
9. Abbott Presents Long-Term Data From Extension Study Showing Adult Crohns Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
10. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
11. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., NEW YORK, Nov. 25 Reportlinker.c...available in its catalogue: ,, Mammography Eq...p://www.reportlinker.com/p0164330/Mammography-Equi...sing incidence of breast cancer in industrialized ...r influencing growth in the mammography market. Gl...
(Date:11/25/2009)..., SAN DIEGO, Nov. 25 N...ompany focused on developing products for minimall...nounced today that it will host a conference call ...30 p.m. PT. The conference call will focus on cur...any,s products and will include comments from mana...
(Date:11/25/2009)... DELFT, The Netherlands and JOHANNESBURG, Novemb...vice division and Pyxis Discovery announced today,... jointly market both,companies, services. , ... lead discovery expertise,will be coupled with iTh...ynthetic chemistry support to projects identified ...
Breaking Medicine Technology:Reportlinker Adds Mammography Equipment - A Global Market Perspective 2Reportlinker Adds Mammography Equipment - A Global Market Perspective 3Reportlinker Adds Mammography Equipment - A Global Market Perspective 4Reportlinker Adds Mammography Equipment - A Global Market Perspective 5Reportlinker Adds Mammography Equipment - A Global Market Perspective 6Reportlinker Adds Mammography Equipment - A Global Market Perspective 7Reportlinker Adds Mammography Equipment - A Global Market Perspective 8NuVasive Announces Conference Call and Webcast Regarding Reimbursement 2NuVasive Announces Conference Call and Webcast Regarding Reimbursement 3NuVasive Announces Conference Call and Webcast Regarding Reimbursement 4iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Legendary TV Producer Norman Lear Receives AARPs Highest Honor 60006 1Legendary TV Producer Norman Lear Receives AARPs Highest Honor 60006 2Legendary TV Producer Norman Lear Receives AARPs Highest Honor 60006 3Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 1Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 2Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 3Pulmo BioTech Inc Announces Cash Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Can 14578 4Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 1Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 2Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 3Gauze based NPWT Capable of Achieving Same Treatment Goals as Foam based NPWT 5665 4
...s,Inc. (Amex: IMM ) today announced results for i... For the three months ended September 30, 2007, r...or the three months ended September,30, 2006. The ...lating to a,licensing agreement and research agree...ded September 30, 2007 was $3,466,000, as compared...
... Inc.,(Nasdaq: TRBN ) today announced presentatio...wed that Trubion,s TRU-015 for rheumatoid arthriti... after a single infusion of 800,mg or 1,600 mg. In...data,showing that repeat administration with TRU-0... pharmacokinetic (PK) and pharmacodynamic (PD),pro...
Other Medicine Technology:Immtech Reports Fiscal Second Quarter 2008 Results 2Immtech Reports Fiscal Second Quarter 2008 Results 3Immtech Reports Fiscal Second Quarter 2008 Results 4Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis 2Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis 3Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis 4Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis 5Trubion Pharmaceuticals Announces Presentation of Positive Data From Phase IIb and Re-treatment Studies With TRU-015 in Patients With Rheumatoid Arthritis 6
(Date:11/27/2009)... 27 The Gymboree Corpora..., CFO/COO, will present at the NASDAQ OMX 23rd Inv...Hotel in London, England, on Wednesday, December 2...ve broadcast of The Gymboree Corporation,s present...oree.com, click on "Our Company" at the bottom of ...
(Date:11/27/2009)...ael, Nov. 27 Shamir Opti... leading provider of innovative products and techn...ay that its board of directors had declared a divi... million (approximately NIS 37.62 million based on...ange), or approximately US$ 0.609 (approximately N...
(Date:11/27/2009)...dented medical, economic burdens, study predicts ,...he number of people with diabetes in the United St... a new study predicts. , That would bring the t... disease, up from 23.7 million today. , , At the...tes will triple, the study also warns, rising from...
(Date:11/27/2009)...i-purpose bilingual coloring books designed for ch...ess community to educate - inform parents and chil...sues to Dinosuars to ABC,S and a host of other top...RWEB) November 27, 2009 -- Today’s children ...hem busy any hour of the day, but one of the oldes...
(Date:11/26/2009)... With cold and flu season upon us, ...ices to control the spread of infections and avoid...to keep ourselves healthy, but to avoid transmitti..., MS, CIC (certified in infection-control), nursin...health at Hospital for Special Surgery (HSS) in Ma...
Breaking Medicine News(10 mins):Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 4
...the official congress of the European Heart Rhythm...n meeting on cardiac arrhythmias and pacing. More ...s year,s event, whose two main themes are atrial f...of cardiac arrhythmias and sudden cardiac death (S...
...S. officials say illnesses linked to tainted peanu... TUESDAY, Jan. 27 (HealthDay News) -- The Georgia ...t paste involved in the nationwide salmonella outb...eak, which has now sickened more than 500 people a...
...re Announces Revolutionary New "Stop Snoring Forev...noring is a source of amusement, and it,s swept un...the population snores, and snoring can be an indic...oach to end snoring that fits patients with applia...
...TON, Fla., Jan. 27 The Quantum Group,Inc. (NYSE A...today that,PWeR(TM) (Personal Wellness electronic ...oped by the Company, may be used by healthcare pro...egan the 2009 e-Prescribing Incentive Program. Th...
...ter pylori , a Gram-negative, flagellated, microae...e human stomach. Its infection is widespread throu...e global human population with 80% in developing c...cosa by macrophages, neutrophils and lymphocytes. ...
...A, Calif., Jan. 27 The non-partisan Consumer Watc...bying effort aimed at allowing the sale of electro...Economic Stimulus legislation. Consumer Watchdog c...h as giving patients the right to an audit detaili...
Other Medicine News:Health News:EUROPACE 2009 2Health News:Salmonella Outbreak Site Has History of Health Violations: Report 2Health News:Spouses of the Lone Star State Rejoice As Snoring Is DOA 2Health News:PWeR(TM) Platform Available to Increase Provider Reimbursements From Medicare 2Health News:PWeR(TM) Platform Available to Increase Provider Reimbursements From Medicare 3Health News:PWeR(TM) Platform Available to Increase Provider Reimbursements From Medicare 4Health News:Helicobacter pylori can multiply in autophagic vesicles 2Health News:Consumer Watchdog Calls on Google to Cease Lobbying Effort to Allow Sale of Patient Medical Records; Urges Congress to Adopt Privacy Protections in Economic Stimulus Bill 2Health News:Consumer Watchdog Calls on Google to Cease Lobbying Effort to Allow Sale of Patient Medical Records; Urges Congress to Adopt Privacy Protections in Economic Stimulus Bill 3Health News:Consumer Watchdog Calls on Google to Cease Lobbying Effort to Allow Sale of Patient Medical Records; Urges Congress to Adopt Privacy Protections in Economic Stimulus Bill 4
...an economically priced 2-channel data acquisition ...he fields of human and animal physiology, pharmaco...try and biomedical engineering. The PowerLab 2/25 ... transducers. Two Pod ports are featured allowing ...
... high-performance data acquisition system suitable...ng human and animal physiology, pharmacology, neur...iomedical engineering. The unit is capable of reco...0 000 samples per second continuously to disk), an...
Worth 4 Dot Test
HOTV Distance Acuity Chart BCDI
Medicine Products: